Broadwood Partners, L.P. Buys 22,189 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 22,189 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were bought at an average price of $17.46 per share, for a total transaction of $387,419.94. Following the completion of the transaction, the insider now owns 12,455,264 shares of the company’s stock, valued at approximately $217,468,909.44. This trade represents a 0.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, April 2nd, Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were acquired at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were acquired at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average price of $21.50 per share, for a total transaction of $176,751.50.

STAAR Surgical Price Performance

Shares of STAA stock opened at $17.60 on Thursday. The company has a market cap of $868.12 million, a P/E ratio of -42.93 and a beta of 0.66. The stock’s 50-day moving average is $19.12 and its 200 day moving average is $24.92. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in STAAR Surgical by 13.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock valued at $2,684,000 after acquiring an additional 13,075 shares in the last quarter. Voloridge Investment Management LLC grew its stake in STAAR Surgical by 9.4% during the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock worth $7,196,000 after buying an additional 25,350 shares during the last quarter. Squarepoint Ops LLC grew its stake in STAAR Surgical by 81.3% during the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock worth $2,844,000 after buying an additional 52,488 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in STAAR Surgical in the fourth quarter valued at about $502,000. Finally, Raiffeisen Bank International AG acquired a new stake in STAAR Surgical in the fourth quarter worth about $1,926,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

STAA has been the subject of several research reports. Stephens reissued an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Finally, StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and a consensus target price of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.